The daily business briefing: May 26, 2020

Novavax starts human trials of coronavirus vaccine, Virgin Orbit's debut launch fails, and more

Coronavirus vaccine candidate
(Image credit: MLADEN ANTONOV/AFP via Getty Images)

1. Novavax launches human testing of COVID-19 vaccine

U.S. biotechnology company Novavax said Monday it was starting human trials of a potential coronavirus vaccine in Australia. "Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID‑19 pandemic," Novavax CEO Stanley Erck said. The results from the first phase of the trials are expected in July, followed by a second phase of testing. Novavax is one of several drugmakers racing to develop vaccines and treatments to fight the novel coronavirus, which has affected about 5.5 million people worldwide and killed nearly 350,000. The U.S. has confirmed nearly 1.7 million cases and more than 98,000 deaths.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Harold Maass, The Week US

Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.